Haemophilia A: from mutation analysis to new therapies
- PMID: 15931172
- DOI: 10.1038/nrg1617
Haemophilia A: from mutation analysis to new therapies
Abstract
Haemophilia is caused by hundreds of different mutations and manifests itself in clinical conditions of varying severity. Despite being inherited in monogenic form, the clinical features of haemophilia can be influenced by other genetic factors, thereby confounding the boundary between monogenic and multifactorial disease. Unlike sufferers of other genetic diseases, haemophiliacs can be treated successfully by intravenous substitution of coagulation factors. Haemophilia is also the most attractive model for developing gene-therapy protocols, as the normal life expectancy of haemophiliacs allows the side effects of gene therapy, as well as its efficiency, to be monitored over long periods.
Similar articles
-
Spectrum of mutations in Albanian patients with haemophilia A: identification of ten novel mutations in the factor VIII gene.Haemophilia. 2007 May;13(3):311-6. doi: 10.1111/j.1365-2516.2007.01459.x. Haemophilia. 2007. PMID: 17498081
-
Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions.Haemophilia. 2005 Sep;11(5):481-91. doi: 10.1111/j.1365-2516.2005.01121.x. Haemophilia. 2005. PMID: 16128892
-
The hemophilias--from royal genes to gene therapy.N Engl J Med. 2001 Jun 7;344(23):1773-9. doi: 10.1056/NEJM200106073442307. N Engl J Med. 2001. PMID: 11396445 Review. No abstract available.
-
[Evaluation of DHPLC analysis for mutation detection in haemophilia A].Cas Lek Cesk. 2006;145(6):484-7. Cas Lek Cesk. 2006. PMID: 16836003 Czech.
-
Preclinical and clinical gene therapy for haemophilia.Haemophilia. 2004 Oct;10 Suppl 4:119-25. doi: 10.1111/j.1365-2516.2004.00984.x. Haemophilia. 2004. PMID: 15479384 Review.
Cited by
-
Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A.PLoS One. 2012;7(9):e44505. doi: 10.1371/journal.pone.0044505. Epub 2012 Sep 4. PLoS One. 2012. PMID: 22973456 Free PMC article.
-
Correction of a Factor VIII genomic inversion with designer-recombinases.Nat Commun. 2022 Jan 20;13(1):422. doi: 10.1038/s41467-022-28080-7. Nat Commun. 2022. PMID: 35058465 Free PMC article.
-
Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases.Genome Res. 2012 Mar;22(3):539-48. doi: 10.1101/gr.129635.111. Epub 2011 Dec 19. Genome Res. 2012. PMID: 22183967 Free PMC article.
-
Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A.Stem Cell Reports. 2018 Dec 11;11(6):1391-1406. doi: 10.1016/j.stemcr.2018.10.012. Epub 2018 Nov 8. Stem Cell Reports. 2018. PMID: 30416049 Free PMC article.
-
Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A.Haematologica. 2015 Jul;100(7):881-92. doi: 10.3324/haematol.2014.123117. Epub 2015 Apr 24. Haematologica. 2015. PMID: 25911555 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical